ATE293977T1 - Nanopartikelzusammensetzungen enthaltend eplerenon - Google Patents

Nanopartikelzusammensetzungen enthaltend eplerenon

Info

Publication number
ATE293977T1
ATE293977T1 AT00980277T AT00980277T ATE293977T1 AT E293977 T1 ATE293977 T1 AT E293977T1 AT 00980277 T AT00980277 T AT 00980277T AT 00980277 T AT00980277 T AT 00980277T AT E293977 T1 ATE293977 T1 AT E293977T1
Authority
AT
Austria
Prior art keywords
compositions containing
nanoparticle compositions
containing eplerenone
eplerenone
nanoparticle
Prior art date
Application number
AT00980277T
Other languages
English (en)
Inventor
Shilpa S Thosar
Rajeev D Gokhale
Dwain S Tolbert
Subhash Desai
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE293977T1 publication Critical patent/ATE293977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00980277T 1999-12-08 2000-12-04 Nanopartikelzusammensetzungen enthaltend eplerenon ATE293977T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16965899P 1999-12-08 1999-12-08
US20898100P 2000-06-02 2000-06-02
PCT/US2000/030179 WO2001041770A2 (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions

Publications (1)

Publication Number Publication Date
ATE293977T1 true ATE293977T1 (de) 2005-05-15

Family

ID=26865266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980277T ATE293977T1 (de) 1999-12-08 2000-12-04 Nanopartikelzusammensetzungen enthaltend eplerenon

Country Status (13)

Country Link
US (2) US20020006919A1 (de)
EP (1) EP1175220B1 (de)
AR (1) AR026745A1 (de)
AT (1) ATE293977T1 (de)
AU (1) AU1756201A (de)
CO (1) CO5251419A1 (de)
DE (1) DE60019741T2 (de)
DK (1) DK1175220T3 (de)
ES (1) ES2240209T3 (de)
HK (1) HK1039897A1 (de)
PE (1) PE20010910A1 (de)
PT (1) PT1175220E (de)
WO (1) WO2001041770A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
WO2007059422A2 (en) * 2005-11-10 2007-05-24 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and method of making same
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008011051A1 (en) * 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2010513325A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬組成物
US20100266692A1 (en) * 2007-07-13 2010-10-21 Corey Jay Bloom Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US9082409B2 (en) * 2008-08-28 2015-07-14 Avaya Inc. Binary-caching for XML documents with embedded executable code
EP2201977A1 (de) * 2008-12-23 2010-06-30 Siegfried Generics International AG Dosiervorrichtung zur Erzeugung eines Gasstromes mit einem in diesem fein verteilten Wirkstoff
CA2782655A1 (en) * 2009-01-06 2010-07-15 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
EA026450B1 (ru) 2011-11-25 2017-04-28 Махмут Билджик Ингалятор
CN103263398B (zh) * 2013-06-06 2014-05-14 山东罗欣药业股份有限公司 一种头孢地尼组合物胶囊及其制备方法
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
CN109925293B (zh) * 2019-03-15 2022-02-01 南京卡文迪许生物工程技术有限公司 依普利酮口服固体制剂及其制备方法
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
MX2023015529A (es) 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)

Also Published As

Publication number Publication date
PE20010910A1 (es) 2001-09-10
US20030212053A1 (en) 2003-11-13
PT1175220E (pt) 2005-07-29
WO2001041770A3 (en) 2001-11-22
HK1039897A1 (zh) 2002-05-17
EP1175220B1 (de) 2005-04-27
US20020006919A1 (en) 2002-01-17
AR026745A1 (es) 2003-02-26
DK1175220T3 (da) 2005-08-29
DE60019741D1 (de) 2005-06-02
ES2240209T3 (es) 2005-10-16
DE60019741T2 (de) 2006-03-02
WO2001041770A2 (en) 2001-06-14
EP1175220A2 (de) 2002-01-30
AU1756201A (en) 2001-06-18
CO5251419A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
DE60019741D1 (de) Nanopartikelzusammensetzungen enthaltend eplerenon
DE60016903D1 (de) Antiperspirant-zusammensetzungen
ITMI991754A0 (it) Composizioni cosmetiche
PT1242087E (pt) Composicoes farmaceuticas
NO20012782L (no) Mikroniserte eplerenon sammensetninger
DE69900634D1 (de) Shampoozusammensetzungen
IS5046A (is) Lyfjasamsetningar
HUP0202275A3 (en) Mousse-forming shampoo compositions
DE60027029D1 (de) Kombinierte impfstoffzusammensetzungen
DE60007969D1 (de) Shampoozusammensetzungen
AR028087A1 (es) Composiciones cosmeticas
NO20021115D0 (no) Ny sammensetning
PL352963A1 (pl) Kompozycje przeciwpotowe
DE60025624D1 (de) Farbstabile polyarylat enthaltende zusammensetzungen
FI990089L (fi) Maalikoostumukset
DE69943245D1 (de) Gaserzeugende zusammensetzung
PT1239832E (pt) Composicoes farmaceuticas
AR027959A1 (es) Composiciones cosmeticas
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
DE60008839D1 (de) Duftstoff-Zusammensetzung
FIU990494U0 (fi) Uusi koostumus
ATE297187T1 (de) Resorcinenthaltende zusammensetzung
AR027981A1 (es) Composiciones cosmeticas
ID27329A (id) Komposisi penghambat
EE04217B1 (et) Farmatseutilised kompositsioonid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175220

Country of ref document: EP

REN Ceased due to non-payment of the annual fee